OXON

Executive Summary

OXON is a European Contract Research Organization (CRO) founded in 2019 and headquartered in Barcelona, Spain. The company specializes in generating Real-World Evidence (RWE) and conducting late-phase research, including non-interventional studies and pragmatic trials, to support drug safety, market access, and development. It offers end-to-end services from feasibility analysis to biostatistics and medical writing for pharmaceutical and medical device clients. As a private company with no disclosed financials, OXON operates in the growing RWE market, driven by regulatory demands for real-world data. Its competitive edge lies in its specialized focus and European base, though it faces competition from larger global CROs. The company's modest size and recent founding suggest potential for growth through strategic partnerships and expansion of service offerings.

Upcoming Catalysts (preview)

• Q4 2026Securing a major pharma partnership for late-phase studies40% success
• Q2 2027Expansion into new therapeutic areas or geographies35% success
• TBDLaunch of a proprietary technology platform for RWE analytics25% success